The Pharmaceuticals and Medical Devices Agency (PMDA) is considering raising its review fees for drugs and medical devices as its financial conditions are likely to deteriorate in the review segment. Negotiations with industry groups are now underway. Explaining the current…
To read the full story
Related Article
- FPMAJ Accepts PMDA’s Fee Raise Plan, but Wants Tradeoff
December 16, 2016
- PMDA Fastest in Granting New Drug Approvals
November 4, 2016
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





